This is a multicohort phase 2 study to evaluate the efficacy of pembrolizumab combined with
the investigational drug sitravatinib in the frontline treatment of advanced, non-squamous
PD-L1 positive NSCLC. For clinical analysis, there will be two patient cohorts defined by
PD-L1 status: Cohort 1 for patients with PD-L1 Tumor Proportion Score (TPS) 1-49% and Cohort
2 for patients with TPS≥50%. The investigators will implement a Simon's two-stage design to
evaluate the efficacy of sitravatinib in combination with pembrolizumab for each cohort
There will be two groups within each cohort of this study: the "main study population" (Group
A) in which patients will receive pembrolizumab plus sitravatinib beginning on Cycle 1 Day 1
(C1D1), and a "pembrolizumab run-in population" (Group B) in which patients will receive
pembrolizumab alone for 1 dose followed by pembrolizumab plus sitravatinib beginning C2D1.
The primary endpoint of the trial is the ORR for patients treated with pembrolizumab plus
sitravatinib in the main study population. The purpose of the pembrolizumab run-in population
is to obtain tissue and blood samples from these patients to be used as controls for
correlative studies and to determine the preliminary efficacy of pembrolizumab alone followed
by the combination.
(1) The primary objective of this study is to evaluate the efficacy of sitravatinib in
combination with pembrolizumab in the front-line treatment of patients with advanced
non-squamous PD-L1 positive NSCLC by measuring Objective Response Rate (ORR).
1. To evaluate other measures of efficacy including Overall Survival (OS), Progression Free
Survival (PFS), Duration of Response (DOR) and Clinical Benefit Rate (CBR) in the
first-line setting for patients with advanced, non-squamous, PD-L1 positive NSCLC
treated with the combination of sitravatinib and pembrolizumab.
2. To evaluate the toxicity profile and tolerability of sitravatinib/pembrolizumab in
advanced, treatment naïve, non-squamous, PD-L1 positive NSCLC.
1. To evaluate ORR, OS, PFS, DOR, and CBR in patients with advanced, non-squamous,
treatment naïve, PD-L1 positive NSCLC who receive pembrolizumab run-in followed by
pembrolizumab/sitravatinib combination therapy.
2. To evaluate the CNS activity of sitravatinib/pembrolizumab in patients with advanced,
treatment naïve, PD-L1 positive NSCLC by measuring Intracranial Objective Response Rate
(iORR) and Intracranial Duration of Response(iDOR) in patients with baseline CNS
disease, and Intercranial Progression-Free Survival (iPFS) in all patients.
3. To study correlates of the adaptive and innate immune responses induced by sitravatinib
and pembrolizumab treatment in both tumor tissue and peripheral blood.
4. To explore the association between tumor immune contexture and clinical benefit to
sitravatinib and pembrolizumab.
In order to be to be eligible to participate in this study, an individual must meet all of
the following criteria:
- Histologically or cytologically confirmed non-squamous NSCLC that is metastatic (Stage
IV), recurrent, or unresectable locally advanced (Stage IIIB/IIIC) disease, not
amenable to treatment with curative intent.
- No prior systemic therapy for advanced disease. Prior chemotherapy for local or
locally advanced disease is allowed if completed >6 months prior to trial enrollment.
Prior immunotherapy is not allowed.
- PD-L1 ≥ 1%.
- Age ≥ 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Life expectancy of at least 3 months.
- Measurable disease as per RECIST v1.1
- Adequate bone marrow and organ function demonstrated by:
- Absolute neutrophil count >1,500/mm3 (1.5 × 10^9/L).
- Hemoglobin ≥ 8.0 g/dL not dependent on transfusion support.
- Platelet count ≥ 75 × 10^9/L (≥ 75,000 per mm3).
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5 × ULN
without liver metastases; < 5.0 x ULN if documented liver metastases
- Serum total bilirubin ≤ ULN, or for patients with potential Gilbert's, direct
bilirubin ≤ ULN
- Calculated creatinine clearance ≥ 40 mL/min, using the Cockcroft-Gault formula.
- Women of child-bearing potential (WOCBP) or men whose partner is a WOCBP agrees to use
contraception while participating in this study, and for a period of 6 months
following termination of study treatment.
- Completed informed consent process, including signing IRB approved informed consent
- Willing to comply with clinical trial instructions and requirements.
An individual who meets any of the following criteria will be excluded from participation
in this study:
- Symptomatic or untreated brain metastases ≥ 2cm in diameter. Patients with brain
lesions that are adequately treated with local therapy (i.e. radiation therapy) and
neurologically stable without the need for corticosteroids for at least 2 weeks prior
to enrollment are allowed. Patients with brain lesions that are asymptomatic, smaller
than 2cm, in non-critical regions of the brain and not requiring corticosteroids for
at least 2 weeks prior to enrollment may be eligible after review with the Sponsor
- Leptomeningeal disease
- Known mutations/alterations in EGFR, ROS1, ALK, or BRAF
- Any prior treatment with checkpoint inhibitor therapy or other immunotherapy agents
- Any prior treatment with therapy having the same mechanism of action as sitravatinib
(e.g., tyrosine kinase inhibitor with a similar target profile or
- Active or prior documented autoimmune disease within the past 2 years (note: patients
with type 1 diabetes, vitiligo, Graves' disease, hypothyroidism due to an autoimmune
condition only requiring hormone replacement, or psoriasis not requiring systemic
treatment (within the past 2 years) are not excluded).
- Active or prior immunocompromising conditions, including use of immunosuppressive
medication within 2 weeks of enrollment. This does not include topical, intranasal or
inhaled steroids with minimal systemic absorption or systemic corticosteroids at
physiologic doses not to exceed 10mg/day of prednisone or equivalent. Use of higher
dose corticosteroids for short/defined course (ie prophylaxis in patients with
contrast dye allergy) is also allowed if indicated.
- Uncontrolled HIV. Patients with HIV may be eligible if they meet the following
- CD4+ T cell count>350 cell/uL
- No history of AIDS-defining opportunistic infection within the past 12 months
- Currently tolerating treatment with ART for at least 4 weeks prior to enrollment,
with HIV viral load <400 copies/mL
- Patients on specific ART drugs with possibility for drug-drug interaction with
sitravatinib may be excluded (see appendix 5).
- Active hepatitis C (HCV) infection. Patients with a history of HCV may be eligible if
they have completed curative antiviral treatment with undetectable HCV viral load and
liver function tests are otherwise within acceptable limits (as described in Section
4.5.2). Patients with chronic Hepatitis B (HBV) infection are not excluded if liver
function is within acceptable limits, but should be evaluated for reactivation risk
and started on suppressive antiviral therapy prior to enrollment if appropriate.
- Need for treatment with a proton pump inhibitor (antacids and/or H2 antagonist are
- History of stroke or transient ischemic attack within the previous 6 months.
- History of life threatening venous thromboembolic event (such as hemodynamically
significant pulmonary embolism) or any arterial thrombotic event within the previous 6
months. Patients with non-life threatening venous thromboembolic events are not
excluded and should be managed with anti-coagulation as per standard institutional
- Any of the following cardiac abnormalities:
- Unstable angina pectoris within the past 6 months.
- Congestive heart failure ≥ NYHA Class 3 within the past 6 months.
- Prolonged QTc on electrocardiogram >500 milliseconds.
- Left ventricular ejection fraction (LVEF) < 40%.
- Uncontrolled hypertension (>150mm Hg or >100mm Hg diastolic) on multiple observations
despite standard of care treatment
- Major surgery within 4 weeks of the date of randomization.
- History of significant hemoptysis or hemorrhage within 4 weeks of the date of
- Known or suspected presence of another malignancy that could be mistaken for the
malignancy under study during disease assessments.
- Has received a live vaccine within 30 days prior to the first dose of trial treatment.
- Pregnancy. WOCBP must have a negative serum or urine pregnancy test documented within
the screening period prior to the date of randomization.
- Breast-feeding or planning to breast-feed during the study or within 30 days following
the last dose of sitravatinib and within 5 months following the last dose of
- Any serious illness, uncontrolled inter-current illness, psychiatric illness, active
or uncontrolled infection, or other medical history, including laboratory results,
which, in the Investigator's opinion, would be likely to interfere with the patient's
participation in the study, or with the interpretation of the results.